原始来源记录
决策级顶线结果
Ultragenyx:UX143第3期Orbit/Cosmic研究的最终分析预计于2025年底公布
该文件指出，setrusumab (UX143) 在成骨不全症中的 Phase 3 Orbit 和 Cosmic 研究正在推进，最终分析将在患者接受治疗至少 18 个月后进行。这些研究的数据预计在 2025 年底左右公布。
关键事实
- 申报时间
- 2025年11月4日 21:12
- 事件
- 顶线结果
- 方向
- 中性
- 来源
- SEC 8-K
- 可信度
- 有来源
来源摘录
EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million Bolstered balance sheet with $400 million proceeds from sale of portion of Crysvita royalty interest NOVATO, Calif. – November 04, 2025 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies